Effect of PD-1 Antibody (SHR-1210) Combined with Capecitabine Treatment After Resection of Intrahepatic Cholangiocarcinoma with High Risk of Recurrence : a Phase 2 Study.
试验速览
- 阶段
- 2 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 65
- 试验地点
- 1
- 主要终点
- recurrence-free survival
研究概览
简要总结
SHR-1210 is a humanized anti-PD-1 Immunoglobulin G4 (IgG4) monoclonal antibody. This is an open- label,single center,non-randomized ,single arm exploratory study . This clinical study is an investigator-initiated clinical trial(IIT) .The objective of this study is to evaluate the efficacy and safety of therapy with anti-PD-1 antibody SHR-1210 plus Capecitabine in patients with Intrahepatic Cholangiocarcinoma After Surgery.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •age:18-75 years, male or femal;
- •Intrahepatic Cholangiocarcinoma confirmed by histopathology, R0 resection was classified as Stage IB, Stage II, Stage IIIA, Stage IIIB, or Stage IA with histolgoic grade G3 according to AJCC TNM (8th edition, 2017);
- •No extrahepatic metastases;
- •preoperative assessment of Child-Pugh A，ECOG Performance Status 0-1;
- •Subjects with chronic HBV infection must have HBV-DNA <500 IU / ml;
- •Functional indicators of vital organs meet the following requirements: Neutrophils ≥1.5*109/L; platelets≥50*109/L; hemoglobin≥90g/l; Alanine aminotransferase （ALT） and Aspartate aminotransferase （AST） ≤ 2.5 times ULN,total bilirubin≤1.5 ULN; International standardized ratio (INR) ≤2.3ULN,creatinine ≤1.5 ULN;
- •No tumor recurrence or metastasis was observed.
排除标准
- •Pathological diagnosis of hepatocellular carcinoma, mixed liver cancer, hilar bile duct cancer;
- •No anti-tumor treatment for Intrahepatic Cholangiocarcinoma, including chemotherapy and topical treatment, before surgery;
- •Known history of hypersensitivity to macromolecular protein preparation or any components of the SHR- 1210 formulation;
- •Tumors are not completely removed, or postoperative pathology suggests non-Intrahepatic Cholangiocarcinoma or other malignant components;
- •Subjects with any active autoimmune disease or history of autoimmune disease;
- •Uncontrolled clinically significant heart disease, including but not limited to the following: (1) > NYHA II congestive heart failure; (2) unstable angina, (3) myocardial infarction within the past 1 year; (4) clinically significant supraventricular arrhythmia or ventricular arrhythmia requirement for treatment or intervention;
- •Active infection or an unexplained fever > 38.5°C during screening or before the first scheduled day of dosing (subjects with tumor fever may be enrolled at the discretion of the investigator);
- •Received a live vaccine within 4 weeks of the first dose of study medication;
- •.Pregnancy or breast feeding;
- •Decision of unsuitableness by principal investigator or physician-in- charge.
研究组 & 干预措施
Combined the therapy using Capecitabine and PD-1
PD1 antibody SHR-1210 D1 200 mg every three weeks; Three weeks is a course of treatment with a total of 8 courses, or the patient has tumor recurrence or metastasis (requires imaging to determine tumor recurrence or metastasis) Capecitabine 2500mg / m2, 2 times/d for 2 weeks, followed by 1 week of stopping ,Three weeks is a course of treatment with a total of 8 courses, or the patient has tumor recurrence or metastasis (requires imaging to determine tumor recurrence or metastasis)
干预措施: PD-1 blocking antibody SHR-1210 (Drug)
Combined the therapy using Capecitabine and PD-1
PD1 antibody SHR-1210 D1 200 mg every three weeks; Three weeks is a course of treatment with a total of 8 courses, or the patient has tumor recurrence or metastasis (requires imaging to determine tumor recurrence or metastasis) Capecitabine 2500mg / m2, 2 times/d for 2 weeks, followed by 1 week of stopping ,Three weeks is a course of treatment with a total of 8 courses, or the patient has tumor recurrence or metastasis (requires imaging to determine tumor recurrence or metastasis)
干预措施: Capecitabine (Drug)
结局指标
主要结局
recurrence-free survival
时间窗: 24 months
From the date of enrollment to the date of diagnosis of tumor recurrence
次要结局
- overall survival(24 months)
- the potential side effects(24 months)
研究者
Jian Zhou
professor
Shanghai Zhongshan Hospital